Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Catalent Inc. Stock

Price
Target price
-

-

-
-
-
-
 
WKN: A112H2 / Name: Catalent / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Catalent Inc. in the next few years
Wizard

Catalent Inc. Stock

For the coming years our community has positive and negative things to say abot the Catalent Inc. stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Revenue growth" there were negative voices in the community.
What does Catalent do?

Pros and Cons of Catalent Inc. in the next few years

Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Catalent Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Catalent Inc. - - - - - - -
Repligen Corp. 2.460% -3.840% 9.471% 0.990% 2.001% -20.153% -7.425%
Opko Health Inc. 1.450% -1.795% -6.109% -24.245% -21.224% -19.615% -71.886%
Amicus Therapeutics Inc. -1.180% -1.183% 7.742% -11.170% -8.743% -27.252% -56.053%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon reviewing the financials of pharmaceutical company Catalent (US symbol: ), it becomes clear that the company is experiencing growth and expansion over time. There has been a consistent increase in total assets, gross profit, and total revenues, which indicates overall improvements in their performance.

Increasing total assets: The total assets of Catalent have been on the rise, from $7.78 billion in 2020 to $9.11 billion in 2021, and then reaching $10.51 billion in 2022. This demonstrates a strong balance sheet, suggesting the company can maintain operations during periods of uncertainty or economic downturns.

Rising total revenues: The company's revenues have consistently increased from $3.09 billion in 2020 to $3.99 billion in 2021, and further to $4.83 billion in 2022. This indicates the company's sales performance and ability to generate income is on an upward trend.

Show more

Comments

Sell Catalent Inc.
Show more

GraveDigger 
0
Report Share
13.11.20 Sell 11.43%
Show more
Not a member yet? Sign up for free!

News

Down 45% Year-to-Date, Novo Nordisk Ignites a Price War: https://www.marketbeat.com/logos/articles/med_20251118143343_down-45-year-to-date-novo-nordisk-ignites-a-price.jpg
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War

For investors in Novo Nordisk (NYSE: NVO), 2025 has been a challenging year. After reaching a 52-week high of over $112, the stock has declined by approximately 45%, reflecting mounting

MarketBeat 
0 19.11.25
Why Scholar Rock Stock Got Socked on Monday: https://g.foolcdn.com/editorial/images/837605/person-checking-medicine-on-a-shelf-in-a-pharmacy.jpg
Why Scholar Rock Stock Got Socked on Monday

A potential delay in an important submission was the news item driving Scholar Rock's (NASDAQ: SRRK) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more

TheMotleyFool 
0 13.10.25